Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients From the WARCEF Trial

作者：Teerlink John R; Qian Min; Bello Natalie A; Freudenberger Ronald S; Levin Bruce; Di Tullio Marco R; Graham Susan; Mann Douglas L; Sacco Ralph L; Mohr J P; Lip Gregory Y H; Labovitz Arthur J; Lee Seitetz C; Ponikowski Piotr; Lok Dirk J; Anker Stefan D; Thompson John L P; Homma Shunichi^*

来源：JACC-Heart Failure, 2017, 5(8): 603-610.

DOI：10.1016/j.jchf.2017.04.011

• aspirin
• heart failure
• hospitalization
• survival
• warfarin

OBJECTIVES The aim of this study was to determine whether aspirin increases heart failure (HF) hospitalization or death in patients with HF with reduced ejection fraction receiving an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB).
BACKGROUND Because of its cyclooxygenase inhibiting properties, aspirin has been postulated to increase HF events in patients treated with ACE inhibitors or ARBs. However, no large randomized trial has addressed the clinical relevance of this issue.
METHODS We compared aspirin and warfarin for HF events (hospitalization, death, or both) in the 2,305 patients enrolled in the WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) trial (98.6% on ACE inhibitor or ARB treatment), using conventional Cox models for time to first event (489 events). In addition, to examine multiple HF hospitalizations, we used 2 extended Cox models, a conditional model and a total time marginal model, in time to recurrent event analyses (1,078 events).
RESULTS After adjustment for baseline covariates, aspirin-and warfarin-treated patients did not differ in time to first HF event (adjusted hazard ratio: 0.87; 95% confidence interval: 0.72 to 1.04; p = 0.117) or first hospitalization alone (adjusted hazard ratio: 0.88; 95% confidence interval: 0.73 to 1.06; p = 0.168). The extended Cox models also found no significant differences in all HF events or in HF hospitalizations alone after adjustment for covariates.
CONCLUSIONS Among patients with HF with reduced ejection fraction in the WARCEF trial, there was no significant difference in risk of HF events between the aspirin and warfarin-treated patients.

• 出版日期2017-8